AC Immune (ACIU) Cash from Operations Growth (1y) (2016 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 60.84% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 85.14% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.72% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 74.39% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 3.23% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 158.60% |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -409.02% |
| Sep 30, 2025 | -43.05% |
| Jun 30, 2025 | -124.23% |
| Mar 31, 2025 | -1,935.27% |
| Dec 31, 2024 | 136.70% |
| Sep 30, 2024 | -7.06% |
| Jun 30, 2024 | 611.76% |
| Mar 31, 2024 | 106.46% |
| Dec 31, 2023 | -4.59% |
| Sep 30, 2023 | -8.78% |
| Jun 30, 2023 | 21.99% |
| Mar 31, 2023 | 27.51% |
| Dec 31, 2022 | 6.25% |
| Sep 30, 2022 | 11.24% |
| Jun 30, 2022 | -15.11% |
| Mar 31, 2022 | -30.67% |
| Dec 31, 2021 | 10.88% |
| Sep 30, 2021 | 6.80% |
| Jun 30, 2021 | -13.86% |
| Mar 31, 2021 | -91.49% |
| Dec 31, 2020 | -64.11% |
| Sep 30, 2020 | -198.12% |
| Jun 30, 2020 | -2.92% |
| Mar 31, 2020 | -115.12% |
| Dec 31, 2019 | -11.85% |
| Sep 30, 2019 | 243.49% |
| Jun 30, 2019 | -106.88% |
| Mar 31, 2019 | 570.77% |
| Dec 31, 2018 | -100.04% |
| Sep 30, 2018 | 99.96% |
| Jun 30, 2018 | 20.83% |
| Mar 31, 2018 | -18.81% |
| Dec 31, 2017 | 411,464.64% |
| Sep 30, 2017 | -336,805.80% |
| Jun 30, 2017 | -1,938.95% |
| Mar 31, 2017 | -53.07% |
| Dec 31, 2016 | -24.34% |